JPWO2020191344A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020191344A5 JPWO2020191344A5 JP2021556493A JP2021556493A JPWO2020191344A5 JP WO2020191344 A5 JPWO2020191344 A5 JP WO2020191344A5 JP 2021556493 A JP2021556493 A JP 2021556493A JP 2021556493 A JP2021556493 A JP 2021556493A JP WO2020191344 A5 JPWO2020191344 A5 JP WO2020191344A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen binding
- binding protein
- bispecific antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025080864A JP2025122027A (ja) | 2019-03-20 | 2025-05-14 | クローディン６二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821399P | 2019-03-20 | 2019-03-20 | |
| US62/821,399 | 2019-03-20 | ||
| PCT/US2020/023986 WO2020191344A1 (en) | 2019-03-20 | 2020-03-20 | Claudin-6 bispecific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025080864A Division JP2025122027A (ja) | 2019-03-20 | 2025-05-14 | クローディン６二重特異性抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525478A JP2022525478A (ja) | 2022-05-16 |
| JP2022525478A5 JP2022525478A5 (https=) | 2023-03-29 |
| JPWO2020191344A5 true JPWO2020191344A5 (https=) | 2023-03-29 |
| JP7682797B2 JP7682797B2 (ja) | 2025-05-26 |
Family
ID=72521273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556493A Active JP7682797B2 (ja) | 2019-03-20 | 2020-03-20 | クローディン６二重特異性抗体 |
| JP2025080864A Pending JP2025122027A (ja) | 2019-03-20 | 2025-05-14 | クローディン６二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025080864A Pending JP2025122027A (ja) | 2019-03-20 | 2025-05-14 | クローディン６二重特異性抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220177583A1 (https=) |
| EP (1) | EP3941944A4 (https=) |
| JP (2) | JP7682797B2 (https=) |
| CN (1) | CN114206934A (https=) |
| CA (1) | CA3134056A1 (https=) |
| WO (1) | WO2020191344A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020241896A1 (en) | 2019-03-20 | 2021-09-23 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| CR20220049A (es) | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| AU2021374036A1 (en) * | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| CA3212530A1 (en) * | 2021-03-05 | 2022-09-09 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-cldn6 antibody and use thereof |
| JP2024511319A (ja) * | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| KR20240004680A (ko) * | 2021-05-07 | 2024-01-11 | 센티 바이오사이언시스, 인코포레이티드 | 키메라 수용체 및 이의 사용 방법 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| AU2022311053A1 (en) * | 2021-07-15 | 2023-12-14 | BioNTech SE | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
| MX2023015028A (es) * | 2021-09-01 | 2024-02-16 | Biosceptre Aust Pty Ltd | Nuevos aglutinantes del p2x7 disfuncional. |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
| JPWO2023053282A1 (https=) * | 2021-09-29 | 2023-04-06 | ||
| EP4704916A1 (en) * | 2023-04-29 | 2026-03-11 | Innovent Biologics (Suzhou) Co., Ltd. | Modified antibodies, antibody fragments thereof, and antibody-drug conjugates |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US581916A (en) | 1897-05-04 | Harvester | ||
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4342776A (en) | 1979-11-05 | 1982-08-03 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS5839685A (ja) | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体及びその製造法 |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| ATE92499T1 (de) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| NZ235329A (en) | 1989-09-15 | 1992-01-29 | Res Triangle Inst | 20(s or rs)-camptothecin derivatives and pharmaceutical compositions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6407115B1 (en) | 1991-01-16 | 2002-06-18 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| FR2707988B1 (fr) | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| CA2346866A1 (en) | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| CN100522955C (zh) | 2002-08-02 | 2009-08-05 | 伊缪诺金公司 | 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| DE60331455D1 (de) | 2002-10-04 | 2010-04-08 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| NZ580700A (en) | 2007-04-19 | 2012-01-12 | Dong A Pharm Co Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| EP3912643B8 (en) | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| US9321842B2 (en) | 2011-05-13 | 2016-04-26 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014075788A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2017079165A1 (en) | 2015-11-02 | 2017-05-11 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| IL273196B2 (en) * | 2017-09-18 | 2024-11-01 | Univ California | Claudin6 antibodies and methods of treating cancer |
-
2020
- 2020-03-20 JP JP2021556493A patent/JP7682797B2/ja active Active
- 2020-03-20 CA CA3134056A patent/CA3134056A1/en active Pending
- 2020-03-20 WO PCT/US2020/023986 patent/WO2020191344A1/en not_active Ceased
- 2020-03-20 EP EP20772537.5A patent/EP3941944A4/en active Pending
- 2020-03-20 US US17/441,183 patent/US20220177583A1/en active Pending
- 2020-03-20 CN CN202080035334.6A patent/CN114206934A/zh active Pending
-
2025
- 2025-05-14 JP JP2025080864A patent/JP2025122027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7757247B2 (ja) | ヒト化またはキメラｃｄ３抗体 | |
| JP7844420B2 (ja) | 新規二重特異性ポリペプチド複合体 | |
| JP2026041734A (ja) | 抗ｃｄ２８及び／又はａｎｔｉ－ｂ７ｈ３組成物 | |
| EP3816185A1 (en) | Multispecific antibody directed against pd-l1 and a tumor-associated antigen | |
| JPWO2021011885A5 (https=) | ||
| TWI815306B (zh) | PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途 | |
| JP2022523442A (ja) | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 | |
| TW202222842A (zh) | 藥物組合物、試劑套組以及使用其治療疾病的方法 | |
| JPWO2020191344A5 (https=) | ||
| KR20140053893A (ko) | 항-cd40 항체 및 사용 방법 | |
| Enever et al. | Next generation immunotherapeutics—honing the magic bullet | |
| WO2020227457A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| IL295996A (en) | Miniature guidance and navigation control (minignc) of antibody-like proteins and methods of production and use thereof | |
| CN115279412A (zh) | 偶联脂肪酸分子的抗体及其用途 | |
| US20240124574A1 (en) | Bispecific Antibodies with Charge Pairs and Uses Thereof | |
| TW202241967A (zh) | 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物 | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JP7730432B2 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| KR20250173553A (ko) | 다발성 골수종의 치료 방법 | |
| Gu et al. | Rationale and development of multispecific antibody drugs | |
| KR20220139930A (ko) | Alppl2 및/또는 alpp에 대한 항원-결합 분자 및 그의 용도 | |
| Vega et al. | New antibody formats | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2025026282A1 (en) | Modified type e multi-specific antibodies |